Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$97.75 USD

97.75
409,224

+0.17 (0.17%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $97.84 +0.09 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Reasons That Make Encompass Health (EHC) an Attractive Bet

by Zacks Equity Research

Encompass Health's (EHC) optimistic business prospects make it a lucrative stock to own for strong gains.

Encompass Health (EHC) Expands Inpatient Rehab Business

by Zacks Equity Research

Encompass Health (EHC) continues to strengthen its inpatient rehabilitation business by opening a hospital.

Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT

by Zacks Equity Research

Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.

Here's Why You Should Retain LHC Group (LHCG) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of buyouts and a broad array of services.

Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive

by Zacks Equity Research

Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.

Why You Should Add Veeva Systems (VEEV) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

Syneos' (SYNH) New Patient Consortium to Drive Innovation

by Zacks Equity Research

Syneos' (SYNH) Patient Voice Consortium incorporates patient perspective across wide range of communities to guide product development lifecycle.

DVA vs. AMED: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. AMED: Which Stock Is the Better Value Option?

Here's Why You Should Retain PRA Health (PRAH) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark

by Zacks Equity Research

Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.

BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch

by Zacks Equity Research

BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.

Cooper Companies (COO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

NextGen (NXGN) Announces Positive Telehealth Survey Results

by Zacks Equity Research

NextGen's (NXGN) recent survey indicates growing preference for telehealth services.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.

HCA Healthcare (HCA) to Rebrand Certain Units in Florida

by Zacks Equity Research

HCA Healthcare (HCA) to adopt the HCA Florida Healthcare brand to enhance its appeal and solidify its presence.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

CVS Health (CVS) Launches Clinical Trial Services Business

by Zacks Equity Research

The latest clinical trial experience from CVS Health (CVS) is expected to overcome multiple challenges posed by its current clinical trial model.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.

PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study

by Zacks Equity Research

PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness remains a woe.

Veeva Systems' (VEEV) Cloud Offerings Aid Drug Development

by Zacks Equity Research

Veeva Systems' (VEEV) Cloud applications help in simplifying and accelerating drug development on an industry-wide basis.

Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Ecolab (ECL) Launches Roach Control Device for Food Outlets

by Zacks Equity Research

Ecolab's (ECL) latest device is expected to help the restaurant industry efficiently protect their brand reputation and eliminate any business and public health risk.